Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)

PHASE3CompletedINTERVENTIONAL
Enrollment

218

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions
Behavioral SymptomsAutistic Disorder
Interventions
DRUG

Aripiprazole

Tablets, Oral, once daily, 8 weeks

DRUG

Placebo

Tablets, Oral, once daily, 8 weeks

Trial Locations (31)

10029

Seaver And New York Autism Center Of Excellence, New York

10312

Richmond Behavioral Associates, Staten Island

11714

North Shore - Long Island Jewish Health System, Bethpage

15203

Western Psychiatric Institute And Clinic, Pittsburgh

22031

Children'S National Medical Center, Fairfax

27710

Duke Child And Family Study Center, Durham

28801

Mission Hospitals, Asheville

30080

Institute For Behavioral Medicine, Smyrna

32611

University Of Florida, Gainesville

33432

Marsella, Gregory, Boca Raton

33613

University Of South Florida, Tampa

35294

University Of Alabama At Birmingham, Birmingham

36303

Harmonex Neuroscience, Dothan

43210

The Nisonger Center, Columbus

48201

Children'S Hospital Of Michigan, Detroit

53201

Children'S Hospital Of Wisconsin, Milwaukee

55101

Regions Hospital, Saint Paul

60606

University Of Illinois At Chicago, Chicago

64108

Children'S Mercy Hospital, Kansas City

68198

Munroe-Meyer Institute, Omaha

73116

Cutting Edge Research, Oklahoma City

75230

Dallas Pediatric Neurology Associates, Dallas

77007

Bayou City Research, Ltd., Houston

80045

The Children'S Hospital, Aurora

85006

Southwest Autism Research And Resource Center, Phoenix

92647

Clinical Innovations, Inc., Huntington Beach

94305

Stanford University School Of Medicine, Stanford

95817

University Of California-Davis Medical Center, Sacramento

98011

Pacific Institute Of Medical Sciences, Bothell

02139

Cambridge Health Alliance, Medford

02481

Ladders Clinic, Wellsley

Sponsors
All Listed Sponsors
collaborator

Otsuka America Pharmaceutical

INDUSTRY

lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY

NCT00337571 - Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD) | Biotech Hunter | Biotech Hunter